Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Next Previous
X
Search
Trial Profile

A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nomlabofusp (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Larimar Therapeutics

    • Most Recent Events

    • 18 Nov 2024 According to a Larimar Therapeutics media release, the company presented data from the Company's Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp at the International Congress for Ataxia Research (ICAR) held from Nov 12-15, 2024 in London, U.K. Data from 61 adults, who participated in these studies, evaluating short-term (up to 28 days) SC doses of 25, 50, 75, and 100 mg nomlabofusp were further evaluated and presented in 3 posters.
    • 19 Oct 2022 According to Larimar Therapeutics media release, the data from phase I clinical program evaluating CTI-1601 for the treatment for Friedreich's Ataxia will be featured in the three presentations at the upcoming International Congress for Ataxia Research. The conference will take place from 1st-4th November 2022 in Dallas, Texas, USA.
    • 19 May 2022 According to a Larimar Therapeutics media release, data from this study will be presented at the 4th Pan American Parkinsons Disease and Movement Disorders Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top